CLEC14A Methylation Marker: Cervical Cancer Screening Data for 431 Participants

A 2026 dataset by Sixian Wang presents methylation levels for the CLEC14A cg05057720 biomarker across a cohort of 431 participants. The data includes 130 normal, 83 LSIL, 195 HSIL, and 23 tumor samples, with median methylation levels reported for each group. It was published on figshare under a CC-BY-4.0 license.

Use Cases

• Validate the diagnostic performance of the CLEC14A cg05057720 methylation marker based on the reported sensitivity and specificity.
• Analyze the progressive increase in methylation levels correlating with lesion severity (normal, LSIL, HSIL, tumor).
• Compare biomarker performance against other screening methods like HPV testing, based on the described limitations of specificity.
• Design risk stratification models for cervical precancerous lesions using the provided methylation data across clinical groups.

Strengths

• Clinical validation cohort includes 431 participant samples with clear group sizes (130 normal, 83 LSIL, 195 HSIL, 23 tumor).
• Reported diagnostic performance metrics include 100% sensitivity and 95.3% specificity for detecting HSIL and invasive cancer.
• Specific median methylation levels are provided for each clinical group (e.g., 0% in normal, 48.6% in tumors).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for large-scale modeling.
• The dataset is very small at 9.2 KB, indicating limited scope.

Provenance

Source

Sixian Wang via figshare.

Collection Method

Data likely generated from a Quantitative Amplification of Specific Methylation (QASM) assay on clinical samples, as described.

Freshness

Last updated 2026-04-14 05:10:15; freshness should be verified.